Valuation: Cerenome, Inc.

Market Cap 25.47M 22.08M 20.69M 18.87M 35.5M 2.43B 36.07M 244M 95.13M 1.22B 95.61M 93.54M 4.06B P/E 2026 *
-0.94x
P/E 2027 * -1.54x
Enterprise Value 25.47M 22.08M 20.69M 18.87M 35.5M 2.43B 36.07M 244M 95.13M 1.22B 95.61M 93.54M 4.06B EV / Sales 2026 *
4.05x
EV / Sales 2027 * 1.33x
Free-Float
98.02%
Yield 2026 *
-
Yield 2027 * -
1 week-4.15%
Current month-4.39%
1 month-11.27%
3 months-35.09%
6 months-46.22%
Current year-71.11%
1 week 3.64
Extreme 3.64
4.03
1 month 3.33
Extreme 3.33
4.31
Current year 2.9
Extreme 2.9
15.32
1 year 2.9
Extreme 2.9
23.42
3 years 2.9
Extreme 2.9
80.25
5 years 2.9
Extreme 2.9
862.5
10 years 2.9
Extreme 2.9
429,377.68
Manager TitleAgeSince
Chief Executive Officer 64 02/04/2014
Director of Finance/CFO 52 06/02/2020
Chief Tech/Sci/R&D Officer - 21/10/2025
Director TitleAgeSince
Director/Board Member 64 01/10/2002
Chairman 77 25/01/2018
Director/Board Member 66 01/01/2020
Date Insider Type Main position Quantity % Market Cap.
1/7/26 Fiscal year

Director

1,844 0.0269%
1/7/26 Fiscal year

Chief Financial Officer

5,970 0.0870%
1/7/26 Fiscal year

Director

1,844 0.0269%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.15%-74.23%-94.08% 25.47M
-2.08%-1.68%+1.99%+13.84% 49.24B
-1.59%+2.12%+460.02%+573.56% 43.3B
-0.85%+7.95%+15.77%+80.09% 40.48B
-0.08%+3.91%+26.96%+9.86% 39.75B
0.00%+3.59%+20.51%+48.00% 32.67B
-3.61%-1.45% - - 16.23B
-2.52%-0.52%+24.35%+118.05% 16.24B
+1.03%+1.46%+4.89%+22.82% 14.04B
-1.09%+5.94%+81.46%+31.15% 13.43B
Average -1.07%+1.66%+62.41%+89.25% 26.54B
Weighted average by Cap. -1.14%+2.71%+96.13%+133.92%

Financials

2026 *2027 *
Net sales 6.3M 5.46M 5.12M 4.66M 8.78M 601M 8.92M 60.23M 23.51M 301M 23.63M 23.12M 1B 19.14M 16.59M 15.55M 14.18M 26.68M 1.83B 27.11M 183M 71.5M 914M 71.86M 70.3M 3.05B
Net income -26.8M -23.23M -21.78M -19.86M -37.36M -2.56B -37.96M -256M -100M -1.28B -101M -98.44M -4.27B -18.45M -16M -15M -13.67M -25.73M -1.76B -26.14M -177M -68.93M -882M -69.28M -67.78M -2.94B
Net Debt - -
Logo Cerenome, Inc.
Plus Therapeutics, Inc. is a healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system (CNS) cancers. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, such as CNSide, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere, is designed to treat many solid organ cancers, including primary and secondary liver cancers by intra-arterial injections.
Employees
28
Date Price Change Volume
13/08/26 US$3.700 0.00% 62,111
12/08/26 US$3.700 -3.39% 65,901
11/08/26 US$3.830 -0.26% 62,768
10/08/26 US$3.840 +0.26% 46,937
07/08/26 US$3.830 -0.78% 68,297
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.700USD
Average target price
36.00USD
Spread / Average Target
+872.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CNSY Stock